补充肌酸对卒中后肌肉质量和力量的影响(ICaRUS卒中试验):一项随机对照试验的研究方案
该研究为随机、双盲、单中心、平行组试验,纳入急性期缺血性卒中患者30例,分为干预组(每日两次、每次10克肌酸)与对照组(每日两次、每次10克安慰剂麦芽糊精),两组均接受蛋白补充和物理治疗,评估功能能力、力量和肌肉质量变化,并随访90天。
要点
- 急性缺血性卒中患者随机接受肌酸或安慰剂,两组均补充蛋白质和物理治疗。
- 主要结局为干预后功能能力、力量和肌肉质量变化。
- 卒中后90天随访功能能力、肌力、死亡率和生活质量。
核心结论
- 研究旨在验证住院期间补充肌酸相较于常规护理对卒中患者功能能力、力量和肌肉质量变化的有效性。
研究设计与样本
- 随机、双盲、单中心、平行组试验,纳入急性期缺血性卒中个体30例,分干预组和对照组。
- 干预组每日两次摄入含10克肌酸的冲剂,对照组每日两次摄入含10克安慰剂(麦芽糊精)的冲剂。
- 两组均接受粉末状牛奶蛋白血清分离物补充以达到每日每公斤体重1.5克蛋白质的目标,并按照当前卒中康复指南接受每日物理治疗。
- 补充仅在7天住院期间提供,个体试验时长约90天,最多三次访视。
主要发现
- 主要结局为干预后功能能力、力量和肌肉质量变化,通过改良Rankin量表、计时起立行走测试、握力、30秒坐站测试、肌肉超声、电生物阻抗和D3-甲基组氨酸肌肉降解标志物评估。
- 探索性亚分析将评估所有参与者的炎症特征。
- 卒中后90天随访评估功能能力、肌肉力量、死亡率和生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke is a leading cause of mortality and disability, and its sequelae are associated with inadequate food intake which can lead to sarcopenia. The aim of this study is to verify the effectiveness of creatine supplementation on functional capacity, strength, and changes in muscle mass during hospitalization for stroke compared to usual care. An exploratory subanalysis will be performed to assess the inflammatory profiles of all participants, in addition to a follow-up 90 days after stroke, to verify functional capacity, muscle strength, mortality, and quality of life. METHODS: Randomized, double-blind, unicenter, parallel-group trial including individuals with ischemic stroke in the acute phase. The duration of the trial for the individual subject will be approximately 90 days, and each subject will attend a maximum of three visits. Clinical, biochemical, anthropometric, body composition, muscle strength, functional capacity, degree of dependence, and quality of life assessments will be performed. Thirty participants will be divided into two groups: intervention (patients will intake one sachet containing 10g of creatine twice a day) and control (patients will intake one sachet containing 10g of placebo [maltodextrin] twice a day). Both groups will receive supplementation with powdered milk protein serum isolate to achieve the goal of 1.5g of protein/kg of body weight/day and daily physiotherapy according to the current rehabilitation guidelines for patients with stroke. Supplementation will be offered during the 7-day hospitalization. The primary outcomes will be functional capacity, strength, and changes in muscle mass after the intervention as assessed by the Modified Rankin Scale, Timed Up and Go test, handgrip strength, 30-s chair stand test, muscle ultrasonography, electrical bioimpedance, and identification of muscle degradation markers by D3-methylhistidine. Follow-up will be performed 90 days after stroke to verify functional capacity, muscle strength, mortality, and quality of life. DISCUSSION: The older population has specific nutrient needs, especially for muscle mass and function maintenance. Considering that stroke is a potentially disabling event that can lead the affected individual to present with numerous sequelae, it is crucial to study the mechanisms of muscle mass loss and understand how adequate supplementation can help these patients to better recover. TRIAL REGISTRATION: The Brazilian Clinical Trials Registry (ReBEC) RBR-9q7gg4 . Registered on 21 January 2019.
引用
- de Souza JT, Minicucci MF, Ferreira NC, et al. Influence of CReatine supplementation on mUScle mass and strength after stroke (ICaRUS Stroke Trial): study protocol for a randomized controlled trial. Trials. 2023. PMID: 36949443. doi:10.1186/s13063-023-07248-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。